Liraglutide vs Trulicity (Dulaglutide): Head-to-Head Efficacy Comparison

How These Two GLP-1 Drugs Compare at a Molecular Level

Liraglutide and dulaglutide both activate the GLP-1 receptor, but their molecular designs differ in ways that shape their clinical profiles. Liraglutide is a modified human GLP-1 analog with 97% amino acid homology to native GLP-1, attached to a C16 fatty acid chain that binds albumin and extends its half-life to approximately 13 hours. This half-life necessitates once-daily injection.

Dulaglutide takes a different engineering approach. It fuses a modified GLP-1 analog to an Fc fragment of human immunoglobulin G4 (IgG4), producing a large molecule with a half-life of roughly 5 days. That longer half-life allows once-weekly dosing. The GLP-1 portion of dulaglutide has about 90% homology to native GLP-1, with specific amino acid substitutions at positions 8 and 22 that resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).

Both drugs slow gastric emptying, stimulate glucose-dependent insulin secretion, and suppress inappropriate glucagon release. The practical difference for patients comes down to injection frequency: seven shots per week versus one. That distinction affects adherence. A 2020 retrospective analysis found that GLP-1 agonist adherence rates were significantly higher with weekly formulations (medication possession ratio 0.69 vs 0.52, P<0.001).

Direct Head-to-Head: The AWARD-6 Trial

The only randomized, double-blind trial directly comparing these two drugs is AWARD-6. This matters because cross-trial comparisons introduce confounders that direct comparisons eliminate. AWARD-6 enrolled 599 adults with type 2 diabetes already on metformin and randomized them to dulaglutide 1.5 mg weekly or liraglutide 1.8 mg daily for 26 weeks.

Results were clear. Mean A1C reduction was 1.42% with dulaglutide versus 1.36% with liraglutide. The difference of 0.06 percentage points met statistical criteria for non-inferiority (upper bound of the 95% CI: 0.12%). Dulaglutide was non-inferior to liraglutide for glycemic control.

Weight loss slightly favored liraglutide: 3.61 kg versus 2.90 kg for dulaglutide. Gastrointestinal side effects occurred at similar rates in both arms: nausea affected 20% of the dulaglutide group and 18% of the liraglutide group. Injection-site reactions were more common with dulaglutide (1.7% vs 0.3%), likely because of the larger injection volume.

The American Diabetes Association's 2024 Standards of Care lists both agents in the same GLP-1 RA category, without ranking one above the other for A1C lowering.

Weight Loss: Where Liraglutide Has a Separate FDA Indication

For weight management specifically, liraglutide holds an advantage that dulaglutide does not: an FDA-approved 3.0 mg dose marketed as Saxenda. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg produced 8.0% mean body weight loss at 56 weeks versus 2.6% with placebo [1]. More than 63% of liraglutide-treated participants lost at least 5% body weight, compared to 27% on placebo.

Dulaglutide does not have a separate obesity indication. Its maximum approved dose for type 2 diabetes is 4.5 mg weekly, introduced in 2020. At that dose, weight loss in the AWARD-11 trial reached approximately 4.6 kg at 36 weeks, meaningful but below what Saxenda achieves.

This distinction matters for patient selection. A person with type 2 diabetes and a BMI of 35 who prioritizes weight loss may benefit more from liraglutide 3.0 mg (or from newer agents like semaglutide or tirzepatide). A person whose primary goal is once-weekly convenience with solid glycemic control may prefer dulaglutide.

Cardiovascular Outcomes: LEADER vs REWIND

Both drugs have completed large cardiovascular outcome trials (CVOTs), and both showed meaningful reductions in major adverse cardiovascular events (MACE). The differences lie in trial design and population.

The LEADER trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg daily or placebo over a median of 3.8 years. The primary outcome (cardiovascular death, nonfatal MI, or nonfatal stroke) occurred in 13.0% of the liraglutide group versus 14.9% on placebo (HR 0.87 to 95% CI 0.78-0.97, P=0.01), per data published in the New England Journal of Medicine.

The REWIND trial took a different approach. It enrolled 9,901 patients with type 2 diabetes, but only 31% had established cardiovascular disease at baseline. The rest had cardiovascular risk factors only. Over a median follow-up of 5.4 years, dulaglutide 1.5 mg weekly reduced the composite MACE endpoint by 12% versus placebo (HR 0.88 to 95% CI 0.79-0.99, P=0.026) [2].

The clinical significance of this distinction: REWIND demonstrated cardiovascular benefit in a broader, lower-risk population than LEADER. Dr. Hertzel Gerstein, the REWIND principal investigator, stated in the trial publication: "These results extend the evidence for cardiovascular benefit of GLP-1 receptor agonists to a broader population of people with type 2 diabetes."

A 2021 meta-analysis of GLP-1 RA cardiovascular trials published in The Lancet Diabetes & Endocrinology found a class-wide 14% reduction in MACE (HR 0.86 to 95% CI 0.80-0.93), suggesting both drugs contribute to a consistent cardiovascular signal across the GLP-1 RA class.

A1C Reduction Across the Dose Ranges

Comparing A1C efficacy requires attention to specific doses. Liraglutide is available at 0.6 mg, 1.2 mg, and 1.8 mg for diabetes (Victoza). Dulaglutide comes in 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg (Trulicity).

At the highest diabetes doses, dulaglutide 4.5 mg produces roughly 1.7 to 1.9% A1C reduction depending on the study population, based on AWARD-11 data. Liraglutide 1.8 mg typically achieves 1.1 to 1.5% A1C reduction across the AWARD, LEAD, and real-world evidence studies.

This gives dulaglutide at its maximum dose a slight edge for glycemic control. The 2023 ADA/EASD consensus report on management of hyperglycemia in type 2 diabetes recommends selecting GLP-1 RAs based on the individual patient's priority: A1C lowering, weight reduction, or cardiovascular risk mitigation.

For patients already on liraglutide 1.8 mg with suboptimal A1C control, switching to dulaglutide 4.5 mg could provide an incremental 0.3 to 0.5% additional reduction, though individual responses vary.

Side Effect Profiles and Tolerability

GLP-1 receptor agonists share a common side effect profile dominated by gastrointestinal symptoms. Nausea, vomiting, and diarrhea are the most frequent adverse events for both drugs. The incidence is comparable.

In the AWARD-6 direct comparison, nausea rates were 20% for dulaglutide and 18% for liraglutide. Diarrhea occurred in 12% and 12%, respectively. Vomiting was reported in 7% of dulaglutide patients and 8% of liraglutide patients. These differences are not clinically meaningful.

One practical tolerability difference: liraglutide's daily dosing allows for a more gradual titration. Patients start at 0.6 mg and increase by 0.6 mg weekly. This slow titration can reduce early nausea. Dulaglutide starts at 0.75 mg weekly, with an increase to 1.5 mg after 4 weeks, offering fewer intermediate steps.

Both drugs carry FDA boxed warnings about medullary thyroid carcinoma risk based on rodent studies, though human data have not confirmed this association. A large pharmacovigilance analysis of GLP-1 RAs published in Diabetes Care found no statistically significant increase in thyroid cancer incidence with these agents in clinical practice.

Pancreatitis is another monitored risk. The incidence in clinical trials is low (0.1 to 0.4%) and similar between the two drugs. Both should be discontinued if pancreatitis is suspected.

Dosing Convenience and Patient Preference

The once-weekly injection schedule of dulaglutide is one of its strongest differentiators. Patient preference studies consistently favor less frequent dosing. A 2015 crossover preference study found that 71% of patients preferred the once-weekly GLP-1 RA over the once-daily option when both provided similar efficacy.

Dulaglutide also uses a pre-filled, single-use pen with a hidden needle that automatically retracts after injection. Liraglutide's Victoza pen requires patients to attach a new needle tip for each injection, dial the dose, and press a button. The Saxenda pen uses the same device. For patients with needle anxiety or dexterity issues, dulaglutide's pen design can reduce barriers to adherence.

Real-world adherence data support this. A retrospective cohort study of over 36,000 patients found that persistence at 12 months was 56% for dulaglutide versus 38% for liraglutide (P<0.001). Fewer injections and a simpler pen drove the difference.

Cost and Insurance Coverage

Both drugs remain expensive at list price. Liraglutide (Victoza, 1.8 mg daily) has a wholesale acquisition cost of approximately $1,100 to $1,300 per month. Dulaglutide (Trulicity, 1.5 mg weekly) lists near $1,000 to $1,100 per month. With insurance, copays vary widely.

A generic version of liraglutide is not yet available in the United States as of mid-2026. Novo Nordisk's patents and regulatory exclusivity on Victoza have faced challenges, but no FDA-approved generic liraglutide injection has reached the market. Dulaglutide similarly lacks a biosimilar competitor.

For the obesity indication, Saxenda (liraglutide 3.0 mg) costs roughly $1,300 to $1,500 per month at list price. Many commercial insurers now cover at least one GLP-1 RA for weight management, though prior authorization requirements are common. Medicare Part D coverage for anti-obesity medications expanded following the Treat and Reduce Obesity Act provisions in recent legislation, though specific formulary placement varies by plan.

Patients should compare their formulary tier for each drug. Some plans place dulaglutide on a preferred tier over liraglutide or vice versa, creating cost differences of $50 to $200 per month at the pharmacy counter.

When to Choose Liraglutide Over Dulaglutide (and Vice Versa)

The Endocrine Society's 2022 clinical practice guideline on pharmacological management of obesity recommends GLP-1 RAs as a drug class, without singling out one agent over another. The choice between liraglutide and dulaglutide should be guided by three factors.

Choose liraglutide when weight loss is the primary goal. At 3.0 mg daily (Saxenda), liraglutide offers FDA-approved obesity treatment with 8% body weight reduction at 56 weeks [1]. No approved obesity-specific dose exists for dulaglutide.

Choose dulaglutide when adherence and convenience matter most. Once-weekly dosing, higher 12-month persistence rates, and a simpler pen device make Trulicity easier for many patients to maintain long term.

Choose dulaglutide when cardiovascular risk is present in a patient who does not meet the high-risk LEADER profile. REWIND demonstrated benefit in a broader population [2], and the 2024 ADA Standards of Care recommend GLP-1 RAs with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease or high risk.

Neither liraglutide nor dulaglutide is first-line if maximal weight loss is the priority. Semaglutide 2.4 mg (Wegovy) produced 14.9% body weight loss at 68 weeks in STEP-1 (N=1,961), and tirzepatide 15 mg (Zepbound) produced 20.9% at 72 weeks in SURMOUNT-1 (N=2,539). Clinicians should consider the full GLP-1 RA and GIP/GLP-1 RA class when selecting therapy.

The starting dose for liraglutide is 0.6 mg subcutaneously once daily, titrated weekly by 0.6 mg increments to a target of 1.8 mg (Victoza) or 3.0 mg (Saxenda). The starting dose for dulaglutide is 0.75 mg subcutaneously once weekly, with increases at 4-week intervals up to 4.5 mg as tolerated.